These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38348585)

  • 1. Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study.
    Nogueira AS; Garcia MAC; Silva MBD; Costa PFD; Frade MAC; Salgado CG; Barreto JG
    Trop Med Int Health; 2024 Apr; 29(4):327-333. PubMed ID: 38348585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermoscopic features of clofazimine-induced pigmentation in a borderline tuberculoid leprosy plaque.
    Behera B; Palit A; Sethy M; Nayak AK; Dash S; Ayyanar P
    Indian J Dermatol Venereol Leprol; 2021; 88(1):85-87. PubMed ID: 34491673
    [No Abstract]   [Full Text] [Related]  

  • 3. Image Gallery: Clofazimine-induced hyperpigmentation of leprosy plaques.
    Bishnoi A; Chatterjee D; Narang T; Dogra S
    Br J Dermatol; 2019 Oct; 181(4):e88. PubMed ID: 31281972
    [No Abstract]   [Full Text] [Related]  

  • 4. Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
    Levis WR; Spencer TI; Ladizinski B
    J Drugs Dermatol; 2010 Aug; 9(8):906. PubMed ID: 20684139
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofazimine: new products. Major antileprous drug.
    Prescrire Int; 1999 Apr; 8(40):44-6. PubMed ID: 10848059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofazimine-induced skin pigmentation.
    Karnan A; Ledwani A
    Pan Afr Med J; 2024; 47():86. PubMed ID: 38737223
    [No Abstract]   [Full Text] [Related]  

  • 8. Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
    Silva IM; Oliveira CA; Guedes WR; Oliveira BB; Oliveira DA; Guedes Filho G
    Braz J Infect Dis; 2009 Apr; 13(2):158-60. PubMed ID: 20140364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofazimine-induced enteropathy in a patient of leprosy.
    Singh H; Azad K; Kaur K
    Indian J Pharmacol; 2013; 45(2):197-8. PubMed ID: 23716903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Borderline Lepromatous Leprosy Therapy Complicated by Type 1 Leprosy Reaction and Adverse Reactions with Dapsone and Clofazimine.
    Matono T; Suzuki S; Mori S; Ato M
    Am J Trop Med Hyg; 2024 Mar; 110(3):483-486. PubMed ID: 38266303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and hematological side effects of clofazimine in leprosy patients.
    Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
    Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
    Maia MV; Cunha Mda G; Cunha CS
    An Bras Dermatol; 2013; 88(2):205-10. PubMed ID: 23739719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline-induced hyperpigmentation in leprosy.
    Fleming CJ; Hunt MJ; Salisbury EL; McCarthy SW; Barnetson RS
    Br J Dermatol; 1996 Apr; 134(4):784-7. PubMed ID: 8733393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
    Goulart IM; Arbex GL; Carneiro MH; Rodrigues MS; Gadia R
    Rev Soc Bras Med Trop; 2002; 35(5):453-60. PubMed ID: 12621663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline tuberculoid leprosy with type 1/reversal reaction.
    Khardenavis S; Deshpande A
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481019
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
    Lim JT; Tan T
    Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
    Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
    Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.